{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:29:11Z","timestamp":1791145751242,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2002,8,23]],"date-time":"2002-08-23T00:00:00Z","timestamp":1030060800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Clin Pharmacol"],"DOI":"10.1186\/1472-6904-2-6","type":"journal-article","created":{"date-parts":[[2002,9,26]],"date-time":"2002-09-26T08:07:27Z","timestamp":1033027647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Appetite suppressants and valvular heart disease \u2013 a systematic review"],"prefix":"10.1186","volume":"2","author":[{"given":"Yoon K","family":"Loke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Derry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angharad","family":"Pritchard-Copley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,8,23]]},"reference":[{"key":"10_CR1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199708283370901","volume":"337","author":"HM Connolly","year":"1997","unstructured":"Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997, 337: 581-588. 10.1056\/NEJM199708283370901.","journal-title":"N Engl J Med"},{"key":"10_CR2","unstructured":"Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep. 1997, 46: 1061-1066."},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0735-1097(99)00315-0","volume":"34","author":"NB Schiller","year":"1999","unstructured":"Schiller NB: Fen\/phen and valvular heart disease: if it sounds too bad to be true, perhaps it isn't. J Am Coll Cardiol. 1999, 34: 1159-1162. 10.1016\/S0735-1097(99)00315-0.","journal-title":"J Am Coll Cardiol"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0167-5273(01)00412-0","volume":"79","author":"AJ Burger","year":"2001","unstructured":"Burger AJ, Charlamb MJ, Singh S, Notarianni M, Blackburn GL, Sherman HB: Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs. Int J Cardiol. 2001, 79: 159-165. 10.1016\/S0167-5273(01)00412-0.","journal-title":"Int J Cardiol"},{"key":"10_CR5","first-page":"13","volume":"19","author":"EA Fisher","year":"1998","unstructured":"Fisher EA, Ruden R: Pulmonary artery pressures and valvular lesions in patients taking diet suppressants. Cardiovasc Rev Rep. 1998, 19: 13-16.","journal-title":"Cardiovasc Rev Rep"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0002-9149(99)00567-6","volume":"84","author":"MK Kancherla","year":"1999","unstructured":"Kancherla MK, Salti HI, Mulderink TA, Parker M, Bonow RO, Mehlman DJ: Echocardiographic prevalence of mitral and\/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. Am J Cardiol. 1999, 84: 1335-1338. 10.1016\/S0002-9149(99)00567-6.","journal-title":"Am J Cardiol"},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0002-9149(00)00840-7","volume":"86","author":"NE Lepor","year":"2000","unstructured":"Lepor NE, Gross SB, Daley WL, Samuels BA, Rizzo MJ, Luko SP, Hickey A, Buchbinder NA, Naqvi TZ: Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease. Am J Cardiol. 2000, 86: 107-110. 10.1016\/S0002-9149(00)00840-7.","journal-title":"Am J Cardiol"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/S0025-6196(11)64213-4","volume":"75","author":"CY Teramae","year":"2000","unstructured":"Teramae CY, Connolly HM, Grogan M, Miller FA: Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc. 2000, 75: 456-461.","journal-title":"Mayo Clin Proc"},{"key":"10_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/j.1550-8528.1998.tb00350.x","volume":"6","author":"TA Wadden","year":"1998","unstructured":"Wadden TA, Berkowitz RI, Silvestry F, Vogt RA, St John Sutton MG, Stunkard AJ, Foster GD, Aber JL: The fen-phen finale: a study of weight loss and valvular heart disease. Obes Res. 1998, 6: 278-284.","journal-title":"Obes Res"},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1001\/jama.283.13.1703","volume":"283","author":"JM Gardin","year":"2000","unstructured":"Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL: Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine\/fenfluramine. JAMA. 2000, 283: 1703-1709. 10.1001\/jama.283.13.1703.","journal-title":"JAMA"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.4065\/74.12.1191","volume":"74","author":"DD Hensrud","year":"1999","unstructured":"Hensrud DD, Connolly HM, Grogan M, Miller FA, Bailey KR, Jensen MD: Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc. 1999, 74: 1191-1197.","journal-title":"Mayo Clin Proc"},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1161\/01.CIR.101.17.2071","volume":"101","author":"JG Jollis","year":"2000","unstructured":"Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T: Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation. 2000, 101: 2071-2077.","journal-title":"Circulation"},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1056\/NEJM199809103391101","volume":"339","author":"MA Khan","year":"1998","unstructured":"Khan MA, Herzog CA, St. Peter JV, Hartley GG, Madlon-Kay R, Dick CD, Asinger RW, Vessey JT: The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 1998, 339: 713-718. 10.1056\/NEJM199809103391101.","journal-title":"N Engl J Med"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1161\/01.CIR.100.21.2161","volume":"100","author":"BK Shively","year":"1999","unstructured":"Shively BK, Roldan CA, Gill EA, Najarian T, Loar SB: Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation. 1999, 100: 2161-2167.","journal-title":"Circulation"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"870","DOI":"10.7326\/0003-4819-129-11_Part_1-199812010-00005","volume":"129","author":"CC Wee","year":"1998","unstructured":"Wee CC, Phillips RS, Aurigemma G, Erban S, Kriegel G, Riley M, Douglas PS: Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med. 1998, 129: 870-874.","journal-title":"Ann Intern Med"},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJM199809103391103","volume":"339","author":"NJ Weissman","year":"1998","unstructured":"Weissman NJ, Tighe JF, Gottdiener JS, Gwynne JT: An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med. 1998, 339: 725-732. 10.1056\/NEJM199809103391103.","journal-title":"N Engl J Med"},{"key":"10_CR17","first-page":"146","volume":"20","author":"NJ Weissman","year":"1999","unstructured":"Weissman NJ: Appetite suppressant valvulopathy: a review of current data. Cardiovasc Rev Rep. 1999, 20: 146-155.","journal-title":"Cardiovasc Rev Rep"},{"key":"10_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.7326\/0003-4819-134-4-200102200-00009","volume":"134","author":"NJ Weissman","year":"2001","unstructured":"Weissman NJ, Panza JA, Tighe JF, Gwynne JT: Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001, 134: 267-273.","journal-title":"Ann Intern Med"},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.7326\/0003-4819-134-4-200102200-00008","volume":"134","author":"ST Mast","year":"2001","unstructured":"Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL: The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med. 2001, 134: 261-266.","journal-title":"Ann Intern Med"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0304-3959(98)00140-7","volume":"78","author":"RA Moore","year":"1998","unstructured":"Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ: Size is everything \u2013 large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain. 1998, 78: 209-216. 10.1016\/S0304-3959(98)00140-7.","journal-title":"Pain"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","volume":"352","author":"D Moher","year":"1998","unstructured":"Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP: Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet. 1998, 352: 609-613. 10.1016\/S0140-6736(98)01085-X.","journal-title":"Lancet"},{"key":"10_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.44.1.16","volume":"44","author":"JH Noseworthy","year":"1994","unstructured":"Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R: The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology. 1994, 44: 16-20.","journal-title":"Neurology"},{"key":"10_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s002280100265","volume":"57","author":"JA Arnaiz","year":"2001","unstructured":"Arnaiz JA, Carn\u00e9 X, Riba N, Codina C, Ribas J, Trilla A: The use of evidence in pharmacovigilance: case reports as the reference source for drug withdrawals. Eur J Clin Pharmacol. 2001, 57: 89-91. 10.1007\/s002280100265.","journal-title":"Eur J Clin Pharmacol"},{"key":"10_CR24","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM199809103391102","volume":"339","author":"H Jick","year":"1998","unstructured":"Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE: A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 1998, 339: 719-724. 10.1056\/NEJM199809103391102.","journal-title":"N Engl J Med"},{"key":"10_CR25","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1001\/jama.283.13.1738","volume":"283","author":"H Jick","year":"2000","unstructured":"Jick H: Heart valve disorders and appetite-suppressant drugs. JAMA. 2000, 283: 1738-1740. 10.1001\/jama.283.13.1738.","journal-title":"JAMA"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1161\/01.CIR.99.1.156","volume":"99","author":"AP Fishman","year":"1999","unstructured":"Fishman AP: Aminorex to fen\/phen: an epidemic foretold. Circulation. 1999, 99: 156-161.","journal-title":"Circulation"},{"key":"10_CR27","unstructured":"British Broadcasting Corporation News: Slimming pill doctor struck off. 18 June 2002, [http:\/\/news.bbc.co.uk\/hi\/english\/uk\/wales\/newsid_1634000\/1634208.stm]"},{"key":"10_CR28","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1136\/bmj.324.7338.679","volume":"324","author":"K Metcalfe","year":"2002","unstructured":"Metcalfe K, Corns C, Fahie-Wilson M, Mackenzie P: Chinese medicines for slimming still cause health problems. BMJ. 2002, 324: 679-10.1136\/bmj.324.7338.679.","journal-title":"BMJ"}],"container-title":["BMC Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6904-2-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6904-2-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6904-2-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6904-2-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T12:03:55Z","timestamp":1726229035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/1472-6904-2-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8,23]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2002,12]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1186\/1472-6904-2-6","relation":{},"ISSN":["1472-6904"],"issn-type":[{"value":"1472-6904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8,23]]},"assertion":[{"value":"21 June 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2002","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"6"}}